PMID- 25873361
OWN - NLM
STAT- MEDLINE
DCOM- 20151215
LR  - 20150916
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 55
IP  - 9
DP  - 2015 Sep
TI  - In vitro study of platelet function confirms the contribution of the ultraviolet 
      B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet 
      concentrates.
PG  - 2219-30
LID - 10.1111/trf.13123 [doi]
AB  - BACKGROUND: Platelet inactivation technologies (PITs) have been shown to increase 
      platelet storage lesions (PSLs). This study investigates amotosalen/ultraviolet 
      (UV)A- and riboflavin/UVB-induced platelet (PLT) lesions in vitro. Particular 
      attention is given to the effect of UVB alone on PLTs. STUDY DESIGN AND METHODS: 
      Buffy coat-derived PLT concentrates (PCs) were treated with amotosalen/UVA, 
      riboflavin/UVB, or UVB alone and compared to untreated PCs throughout storage. In 
      vitro PLT function was assessed by blood gas and metabolite analyses, flow 
      cytometry-based assays (CD62P, JC-1, annexin V, PAC-1), hypotonic shock response, 
      and static adhesion to fibrinogen-coated wells. RESULTS: In our experimental 
      conditions, riboflavin/UVB-treated PCs showed the most pronounced differences 
      compared to untreated and amotosalen/UVA-treated PCs. The riboflavin/UVB 
      treatment led to a significant increase of anaerobic glycolysis rate despite 
      functional mitochondria, a significant increase of CD62P on Day 2, and a decrease 
      of JC-1 aggregates and increase of annexin V on Day 7. The expression of active 
      GPIIbIIIa (PAC-1) and the adhesion to fibrinogen was significantly increased from 
      Day 2 of storage in riboflavin/UVB-treated PCs. Importantly, we showed that these 
      lesions were caused by the UVB radiation alone, independently of the presence of 
      riboflavin. CONCLUSION: The amotosalen/UVA-treated PCs confirmed previously 
      published results with a slight increase of PSLs compared to untreated PCs. 
      Riboflavin/UVB-treated PCs present significant in vitro PSLs compared to 
      untreated PCs. These lesions are caused by the UVB radiation alone and probably 
      involve the generation of reactive oxygen species. The impact of these 
      observations on clinical use must be investigated.
CI  - (c) 2015 AABB.
FAU - Abonnenc, Melanie
AU  - Abonnenc M
AD  - Laboratoire de Recherche sur les Produits Sanguins Epalinges, Transfusion 
      Interregionale CRS, Epalinges, Switzerland.
FAU - Sonego, Giona
AU  - Sonego G
AD  - Laboratoire de Recherche sur les Produits Sanguins Epalinges, Transfusion 
      Interregionale CRS, Epalinges, Switzerland.
FAU - Crettaz, David
AU  - Crettaz D
AD  - Laboratoire de Recherche sur les Produits Sanguins Epalinges, Transfusion 
      Interregionale CRS, Epalinges, Switzerland.
FAU - Aliotta, Alessandro
AU  - Aliotta A
AD  - Laboratoire de Recherche sur les Produits Sanguins Epalinges, Transfusion 
      Interregionale CRS, Epalinges, Switzerland.
FAU - Prudent, Michel
AU  - Prudent M
AD  - Laboratoire de Recherche sur les Produits Sanguins Epalinges, Transfusion 
      Interregionale CRS, Epalinges, Switzerland.
FAU - Tissot, Jean-Daniel
AU  - Tissot JD
AD  - Laboratoire de Recherche sur les Produits Sanguins Epalinges, Transfusion 
      Interregionale CRS, Epalinges, Switzerland.
FAU - Lion, Niels
AU  - Lion N
AD  - Laboratoire de Recherche sur les Produits Sanguins Epalinges, Transfusion 
      Interregionale CRS, Epalinges, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150415
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Annexin A5)
RN  - 0 (Furocoumarins)
RN  - 0 (P-Selectin)
RN  - 0 (SELP protein, human)
RN  - EC 3.1.3.48 (DUSP2 protein, human)
RN  - EC 3.1.3.48 (Dual Specificity Phosphatase 2)
RN  - K1LDZ0VBC0 (amotosalen)
RN  - TLM2976OFR (Riboflavin)
SB  - IM
MH  - Annexin A5/metabolism
MH  - Blood Buffy Coat/metabolism/pathology
MH  - Blood Platelets/*metabolism/pathology
MH  - *Blood Preservation
MH  - Dual Specificity Phosphatase 2/metabolism
MH  - Female
MH  - *Flow Cytometry
MH  - Furocoumarins/blood
MH  - *Glycolysis/drug effects/radiation effects
MH  - Humans
MH  - Male
MH  - Osmotic Pressure/drug effects/radiation effects
MH  - P-Selectin/metabolism
MH  - Platelet Function Tests
MH  - Riboflavin/*pharmacology
MH  - Time Factors
MH  - *Ultraviolet Rays
EDAT- 2015/04/16 06:00
MHDA- 2015/12/17 06:00
CRDT- 2015/04/16 06:00
PHST- 2014/09/04 00:00 [received]
PHST- 2015/02/24 00:00 [revised]
PHST- 2015/02/28 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2015/12/17 06:00 [medline]
AID - 10.1111/trf.13123 [doi]
PST - ppublish
SO  - Transfusion. 2015 Sep;55(9):2219-30. doi: 10.1111/trf.13123. Epub 2015 Apr 15.